Minimizing Postoperative Pain in Autologous Breast Reconstruction With the Omental Fat-Augmented Free Flap.
Abstract
[INTRODUCTION] The omental fat-augmented free flap (O-FAFF) is a recently developed technique for autologous breast reconstruction. Our aim of the study is to evaluate the outcomes of our early case series. We assess the O-FAFF donor site morbidity in terms of postoperative pain, narcotic, and antiemetic use.
[METHODS] A retrospective analysis of patients undergoing O-FAFF from 2019 to 2021 was performed. Patients were evaluated for demographic data, operative time, hospital course, and complications. Mean pain scores (1-10 scale) and narcotic pain medication use in oral morphine equivalents and doses of antiemetic medications during their hospital course were analyzed. We compared outcomes of our O-FAFF group with those of a control group of patients who underwent breast reconstruction with traditional free abdominal tissue transfer.
[RESULTS] A total of 14 patients underwent O-FAFF breast reconstruction, representing 23 breasts. Patients had an average age of 48.5 years (±2.3 years) and body mass index of 22.6 kg/m 2 (±1.09 kg/m 2 ). Average follow-up was 232 days (±51 days). Average mastectomy weight was 245.6 g (±30.2 g) and average O-FAFF weight was 271 g (±31.7 g). Average pain scores on postoperative day 1 (POD1), POD2, and POD3 were 3.1 (±0.28), 2.8 (±0.21), and 2.1 (±0.35), respectively. The average narcotic use by patients in oral morphine equivalents on POD1, POD2, and POD3 are 24.3 (±5.5), 21.9 (±4.6), and 6.2 (±2.4), respectively. Total narcotic use during hospital stay was 79.4 mg (±11.1 mg). Average pain scores and narcotic use are significantly lower when compared with a previously published cohort of patients who underwent autologous breast reconstruction with free abdominal tissue transfer ( P < 0.05). Average antiemetic use was lower in the O-FAFF group compared with the control group: 3.5 versus 4.8 doses ( P = 0.6). Hospital length of stay was 3.0 days (±0.0 days). No complications were noted (0%). Patients were universally satisfied with their reconstructive outcome (100%).
[CONCLUSIONS] The O-FAFF is proven to be a viable method of autologous breast reconstruction. Early series of patients undergoing O-FAFF reconstruction suggest a lower donor site morbidity as demonstrated by lower postoperative pain scores and lower consumptions of narcotic pain medications.
[METHODS] A retrospective analysis of patients undergoing O-FAFF from 2019 to 2021 was performed. Patients were evaluated for demographic data, operative time, hospital course, and complications. Mean pain scores (1-10 scale) and narcotic pain medication use in oral morphine equivalents and doses of antiemetic medications during their hospital course were analyzed. We compared outcomes of our O-FAFF group with those of a control group of patients who underwent breast reconstruction with traditional free abdominal tissue transfer.
[RESULTS] A total of 14 patients underwent O-FAFF breast reconstruction, representing 23 breasts. Patients had an average age of 48.5 years (±2.3 years) and body mass index of 22.6 kg/m 2 (±1.09 kg/m 2 ). Average follow-up was 232 days (±51 days). Average mastectomy weight was 245.6 g (±30.2 g) and average O-FAFF weight was 271 g (±31.7 g). Average pain scores on postoperative day 1 (POD1), POD2, and POD3 were 3.1 (±0.28), 2.8 (±0.21), and 2.1 (±0.35), respectively. The average narcotic use by patients in oral morphine equivalents on POD1, POD2, and POD3 are 24.3 (±5.5), 21.9 (±4.6), and 6.2 (±2.4), respectively. Total narcotic use during hospital stay was 79.4 mg (±11.1 mg). Average pain scores and narcotic use are significantly lower when compared with a previously published cohort of patients who underwent autologous breast reconstruction with free abdominal tissue transfer ( P < 0.05). Average antiemetic use was lower in the O-FAFF group compared with the control group: 3.5 versus 4.8 doses ( P = 0.6). Hospital length of stay was 3.0 days (±0.0 days). No complications were noted (0%). Patients were universally satisfied with their reconstructive outcome (100%).
[CONCLUSIONS] The O-FAFF is proven to be a viable method of autologous breast reconstruction. Early series of patients undergoing O-FAFF reconstruction suggest a lower donor site morbidity as demonstrated by lower postoperative pain scores and lower consumptions of narcotic pain medications.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 6 | |
| 시술 | free flap
|
피판재건술 | dict | 2 | |
| 해부 | Flap
|
scispacy | 1 | ||
| 해부 | oral morphine
|
scispacy | 1 | ||
| 해부 | abdominal tissue
|
scispacy | 1 | ||
| 약물 | morphine
|
C0026549
morphine
|
scispacy | 1 | |
| 약물 | [INTRODUCTION] The
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 약물 | ±2.4
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] The
|
scispacy | 1 | ||
| 질환 | Postoperative Pain
|
C0030201
Pain, Postoperative
|
scispacy | 1 | |
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | breasts
|
scispacy | 1 | ||
| 질환 | oral morphine
|
scispacy | 1 | ||
| 기타 | Omental
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | POD1
→ postoperative day 1
|
scispacy | 1 | ||
| 기타 | POD3
|
scispacy | 1 |
MeSH Terms
Humans; Middle Aged; Female; Free Tissue Flaps; Mastectomy; Retrospective Studies; Antiemetics; Breast Neoplasms; Mammaplasty; Postoperative Pain; Narcotics; Morphine Derivatives
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Endodontic implications of hypercementosis: A systematic review of anatomical challenges and therapeutic strategies.
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Breast plastic surgery in perimenopausal and postmenopausal women: Menopause-informed counseling on screening, safety, and long-term breast health.